NCT02932969

Brief Summary

The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
56

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Oct 2016

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 4, 2016

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

October 12, 2016

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 13, 2016

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 26, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2017

Completed
Last Updated

May 31, 2017

Status Verified

May 1, 2017

Enrollment Period

8 months

First QC Date

October 12, 2016

Last Update Submit

May 30, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety and tolerability of single continuous IV infusion of BMS-986231 in healthy Japanese and Non-Asian participants based on Adverse events, clinical laboratory values, vital signs, ECGs, and physical examinations

    11 days

Study Arms (3)

Panel 1 Arm

EXPERIMENTAL

BMS-986231 and BMS-986231 Placebo intravenously

Drug: BMS-986231Drug: BMS-986231 Placebo

Panel 2 Arm

EXPERIMENTAL

BMS-986231 and BMS-986231 Placebo intravenously

Drug: BMS-986231Drug: BMS-986231 Placebo

Panel 3 Arm

EXPERIMENTAL

BMS-986231 and BMS-986231 Placebo intravenously

Drug: BMS-986231Drug: BMS-986231 Placebo

Interventions

Panel 1 ArmPanel 2 ArmPanel 3 Arm
Panel 1 ArmPanel 2 ArmPanel 3 Arm

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Ancestry
  • First generation Japanese
  • Non-Asian with grandparents and parents of non-Asian descent
  • Body weight greater than or equal to 45kg and less than or equal to 110kg
  • Women of childbearing potential have specific birthcontrol methods
  • Males sexually active with women of childbearing potential have specific birthcontrol methods

You may not qualify if:

  • History of chronic illness
  • Chronic headaches
  • Recurrent dizziness
  • Personal or family history of heart disease
  • Personal history of bleeding diathesis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West Coast Clinical Trials, Llc

Cypress, California, 90630, United States

Location

Related Links

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Bristol-Myers Squibb

    Bristol-Myers Squibb

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 12, 2016

First Posted

October 13, 2016

Study Start

October 4, 2016

Primary Completion

May 26, 2017

Study Completion

May 26, 2017

Last Updated

May 31, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations